Navin Fluorine Q4 FY26: Revenue +34%, PAT +124%

Earnings call: what the company highlighted

Navin Fluorine International Limited used its Q4 and full-year FY26 earnings call to underline sustained operating momentum across its three verticals. Management said FY26 was “resilient” despite a challenging global environment and geopolitical uncertainty, and added that the company has delivered six consecutive quarters of revenue and profitability growth. The company positioned its growth as broad-based, supported by diversification across products, customers, and geographies.

A key theme was the transition of large projects from the investment phase to revenue generation. Management pointed to commissioning and ramp-up plans across refrigerants and fluorochemicals, along with progress on the CHEMOS project. The company also reiterated its intent to keep capital allocation disciplined while maintaining balance-sheet strength.

Final dividend announced

The board declared a final dividend of INR 8.6 per equity share, described as 430% of the face value (face value: INR 2 per share). The dividend announcement came alongside commentary about a strong order book and customer confidence across verticals.

The call also referenced the company’s focus on long-term value creation for stakeholders, tying dividends and capital allocation to sustained execution and market expansion.

Q4 FY26: consolidated financial performance

For the quarter ended March 31, 2026, the company reported consolidated revenues of INR 938 crore, a 34% year-on-year increase. Operating EBITDA rose 80% year-on-year to INR 321 crore, with margin expansion to 34.2%. Operating profit before tax (PBT) increased 118% year-on-year to INR 251 crore.

Profit after tax (PAT) for the quarter was reported at INR 213 crore, implying 124% growth year-on-year. Separately, a quarterly snapshot table in the provided data set shows total revenue of INR 955.30 crore, operating profit of INR 321.15 crore, and net profit of INR 212.62 crore for March 2026. These figures broadly align with the management commentary on scale-up and margin expansion.

FY26: profitability expansion and working capital

For the full year, management said net operating revenues grew 41% year-on-year, supported by momentum across Specialty Chemicals, CDMO, and HPP. Operating EBITDA more than doubled to INR 1,082 crore, with EBITDA margin at 32.6%, described as an expansion of 992 basis points.

Operating PBT rose 142% year-on-year to INR 815 crore (from INR 336 crore in the prior period referenced on the call). Full-year PAT was reported at INR 664 crore versus INR 289 crore.

The company also reported improved cash conversion metrics, with net working capital at 74 days versus 90 days, attributing the improvement to operational efficiency.

Segment performance: HPP, Specialty Chemicals, CDMO

Management provided a detailed segment update for Q4 FY26:

• HPP business: Q4 revenue grew 20% year-on-year to INR 393 crore, driven by improved realizations and volume growth. The company said its AHF plant was successfully commissioned, and commercial supplies commenced during the quarter.
• Specialty Chemicals: Q4 revenue rose 39% year-on-year to INR 360 crore, with management citing execution across existing and new molecules and support from long-term contracts.
• CDMO: Q4 revenue increased 61% year-on-year to INR 186 crore, driven by a mix of early-stage, late-stage, and commercial molecules. Therapeutic areas mentioned included oncology, respiratory, cardiovascular, neurology, and animal health.

Management also stated that EBITDA and PAT grew more than 2x for the year across all three verticals.

Capacity additions and project milestones

On projects, the company highlighted multiple timelines:

• Additional HFC capacities of 32 MPP are expected to be commissioned and ramped up in the new financial year, alongside the upcoming CHEMOS project.
• The HF3 capacity expansion equivalent to 15,000 metric tonnes per annum of R32 remains on track for commissioning in Q3 FY27.
• Specialty Chemicals MPPD debottlenecking capex is targeted for commissioning in Q3 FY27.
• The CHEMOS project was described as on track and expected to be completed by end-June to early-July.

The company linked these milestones to a shift from investment to revenue generation, while reiterating a focus on niche chemistries.

Industry and operating backdrop management is watching

Management said it is monitoring geopolitical developments, particularly for their impact on energy prices, logistics, and supply chain disruptions. In the HPP business, the company cited a constructive global demand-supply environment, increasing adoption of low-GWP refrigerants, and export opportunities.

In Specialty Chemicals and CDMO, management emphasised order visibility and a robust pipeline going into FY27, without providing a quantified order book figure in the shared excerpts.

Key numbers at a glance

Why this quarter matters for investors

The Q4 print stands out for two reasons visible in the numbers: a sharp rise in profitability and a high EBITDA margin above 34% for the quarter. Management attributed the performance to realizations, volumes, execution on molecules, and an improving mix, alongside operating leverage.

The second factor is the project pipeline. Multiple commissioning events and ramp-ups are scheduled over FY27, and management explicitly framed FY27 as a year where key projects move into revenue generation. For investors, that shifts attention to execution timelines, utilization ramp-up, and whether working-capital discipline sustains as volumes grow.

Conclusion

Navin Fluorine closed Q4 FY26 with strong year-on-year growth in revenue and profits, announced a final dividend of INR 8.6 per share, and reiterated that major capex projects are nearing commissioning or ramp-up. The next set of milestones to track, based on management commentary, are the CHEMOS completion by end-June to early-July and commissioning targets extending into Q3 FY27 for R32 and debottlenecking projects.